Phage Systems. Precision Innovation. Beyond Viral Boundaries.

At Phage Biologics, based in Montreal, Canada, we believe bacteriophages — nature’s most abundant and diverse biological entities — are the next great frontier in biotechnology. For more than a century, phages have fascinated scientists as natural viral predators of bacteria, but only now is their true potential being unlocked as therapeutic platforms, vaccine scaffolds, and nanotechnology engines.

Where most CDMOs focus on conventional antibodies or mammalian systems, we exist for the innovators working at the edge of phage science. Our mission is simple: to be the best phage CDMO in Montreal, Canada — and beyond, serving clients across North America, Europe, and the world.

We specialize in filamentous phages (M13, f1), lytic phages (T4, T7), and phage-derived scaffolds for applications across:

  • Phage Therapy – precision antimicrobials against drug-resistant bacteria.
  • Phage Display – discovery of antibodies, peptides, and ligands.
  • Vaccine Platforms & VLPs – immunogenic phage scaffolds for infectious disease and oncology.
  • Nanomaterials – engineered phages as carriers and assembly tools.
Phage Biologics CDMO, From Bacteriophage to Breakthrough-Design to GMP Delivery

Our Philosophy

The CDMO landscape is crowded with generalists. Phage Biologics is different:

  • Phage-First Focus – not a side capability, but our core identity.
  • Niche as Strength – we focus on the molecules that others call “too complex” or “too small.”
  • Technical Elegance – lean, precise processes that unlock scalability and reproducibility.
  • Global Readiness – GMP-grade systems designed to serve clinical programs worldwide.

We see phages not just as viruses — but as programmable biological machines capable of transforming medicine and materials.

Our Capabilities

  • Fermentation & Amplification
    Scalable microbial systems for high-yield production of therapeutic phages and phage-derived platforms, including M13, f1, T4, T7, and fully custom-engineered strains. Flexible infrastructure supports pilot development through GMP-compliant manufacturing.
  • Downstream Processing
    Advanced purification workflows—ultracentrifugation, tangential flow filtration (TFF), and chromatography—designed for consistency and regulatory compliance. Specialized endotoxin reduction strategies ensure safety for clinical applications.
  • Analytics & Characterization
    Comprehensive analytical suite including electron microscopy (EM), qPCR/ddPCR, dynamic light scattering (DLS), and functional bioassays. Our assays validate infectivity, stability, and immunogenicity, providing the datasets required for IND/IMPD filings.
  • GMP Manufacturing
    End-to-end GMP capability for phages, virus-like particles (VLPs), and phage-derived nanomaterials. From pilot lots to clinical-grade production, we offer aseptic fill–finish, QA/QC integration, and full batch traceability.
  • Engineering & Synthetic Biology
    Cutting-edge approaches to phage modification, including CRISPR-based genome editing and synthetic biology design. We enable precise control over capsid proteins, display topologies, and ligand presentation, unlocking new therapeutic and nanomaterial applications.

Who We Partner With

At Phage Biologics, partnerships are at the core of what we do. We believe that advancing the phage field requires collaboration across industries, disciplines, and stages of development. By building phage CDMO partnerships, we connect science with scalable solutions and help innovators turn vision into impact.

We proudly partner with:

  • Biopharma companies developing next-generation phage therapeutics and vaccines, from preclinical programs through GMP manufacturing.
  • Synthetic biology innovators harnessing phage scaffolds for nanomaterials, regenerative medicine, and programmable biological systems.
  • Global health organizations dedicated to addressing antimicrobial resistance with low-cost, scalable, and globally accessible phage-based solutions.
  • Academic researchers and startup pioneers translating discoveries at the lab bench into viable products with real-world clinical and commercial potential.

Each of these partnerships reflects our commitment to supporting innovators at every stage — from early feasibility to large-scale commercialization.

Our Vision

We envision a future where phages are as mainstream as antibodies — powering therapies, vaccines, diagnostics, and nanomaterials.

At Phage Biologics, we are not just manufacturing phages. We are building the future of biologics, from the nanoscale outward.

Phage Biologics. Phage Systems. Precision Innovation. Beyond Viral Boundaries.

Contact our team today at hello@phagebiologics.com